MCL Literature Feed

In a retrospective analysis of 95 MCL cases, specific histopathological patterns of bone marrow involvement were identified as key prognostic indicators, aiding in initial patient risk stratification.

PRMT5 promotes MCL growth via MYC-driven lipid metabolism reprogramming, identifying it as a poor prognostic marker and a novel therapeutic target with preclinical inhibitor activity.

This retrospective study confirms that progression of disease within 24 months (POD24) after initial therapy is a strong negative prognostic marker for overall survival in MCL patients.

In young, newly diagnosed MCL, first-line rituximab, bendamustine, and cytarabine (R-BAP) plus a BTK inhibitor improved complete response and PFS over standard R-CHOP/R-DHAP in a real-world setting.

Gene expression profiling identifies two distinct molecular MCL subtypes, C1 and C2, with C2 showing high proliferation and poor prognosis, providing a powerful new biomarker for risk stratification.

Outpatient autologous stem cell transplantation is a feasible consolidation strategy for advanced MCL in a low-income, Latin American setting, providing important real-world evidence for resource-constrained systems.

This study defines the unique treatment patterns, clinical outcomes, and genomic landscape of Hepatitis B-associated MCL, providing crucial data for managing this complex patient subgroup.

In a European compassionate use program, pirtobrutinib demonstrated a 67% overall response rate and good safety in heavily pretreated, BTKi-exposed relapsed/refractory MCL, supporting its real-world clinical utility.

Real-world registry data from Ukraine (2019-2021) reports a 3-year overall survival of 61% for newly diagnosed MCL patients, providing a crucial benchmark for outcomes in this region.

MNDA is highly expressed in nearly 80% of mantle cell lymphoma cases, but its utility in distinguishing MCL from marginal zone lymphoma is limited due to overlapping expression.

This retrospective analysis shows peripheral blood Ig-HTS MRD testing (clonoSEQ) effectively predicts relapse earlier than imaging in MCL patients, supporting its use as a surveillance tool post-frontline therapy.

MCL with concurrent EZH2 expression and TP53 mutation is frequent and identifies a patient subgroup with a dismal outcome, establishing a powerful negative prognostic biomarker combination.

This paper does not study MCL but finds high Notch1 protein expression in methotrexate-associated DLBCL, suggesting a pathogenic role for this pathway, which is also altered in MCL.

Severe neurotoxicity after brexucabtagene autoleucel is common, associated with MRI/EEG changes and longer hospitalization, but importantly does not negatively impact treatment response or survival in MCL patients.

Phospho-flow cytometry reveals that high constitutive AKT and inducible STAT5/SYK B-cell receptor signaling activity predicts shorter survival and ibrutinib resistance, offering a functional biomarker for high-risk MCL.

This large SEER database study identifies being unmarried, particularly widowed, as an independent negative prognostic factor for survival in MCL, underscoring the need for enhanced psychosocial support.

Large B-cell lymphoma with IRF4 rearrangement can mimic blastoid MCL by presenting in older adults and expressing CD5, but negativity for Cyclin D1 and SOX11 is crucial for differential diagnosis.

This large retrospective study of orbital lymphomas identifies mantle cell lymphoma as a rare subtype but provides no specific clinical or prognostic data for this particular presentation.

This UK real-world study confirms bendamustine-rituximab toxicity rates are similar to clinical trials, identifying MCL histology and poor performance status as key risk factors for serious infections.

A Mendelian randomization study provides causal evidence that genetically predicted longer telomere length increases the risk of developing MCL, suggesting a role for enhanced cellular proliferation in pathogenesis.

This retrospective study found 36% of ibrutinib-treated patients, including MCL, developed serious infections, with prior transplant and steroid use identifying a high-risk group needing potential prophylaxis.

In a mixed lymphoma cohort, this retrospective study found cardiac involvement in 1.5% of patients, primarily DLBCL with pericardial effusion, but provides no specific data on MCL.

This real-world study shows significant MCL-related mortality after first relapse (23%), suggesting high-risk patients may not survive to receive novel therapies, supporting their use in earlier lines.

SOX11 expression in cyclin D1-negative large B-cell neoplasms defines them as a variant of blastoid MCL, not DLBCL, solidifying SOX11 as a crucial diagnostic marker for aggressive MCL.

This retrospective study of 134 patients demonstrates that adding a BTK inhibitor to chemotherapy improves efficacy and prolongs progression-free survival in relapsed/refractory MCL.

This 15-year real-world study benchmarks MCL survival outcomes, reflecting evolving treatment eras and providing crucial prognostic data from routine clinical practice.

Radiation therapy is a feasible bridging strategy to control disease in relapsed/refractory MCL patients awaiting CAR-T infusion, potentially improving eligibility and outcomes for those with bulky disease.

This indirect comparison of ZUMA-2 (brexucabtagene autoleucel) and SCHOLAR-2 (standard of care) demonstrates a substantial overall survival benefit for CAR-T therapy in relapsed/refractory MCL after BTKi failure.

Combining the MCL35 gene signature with s-MIPI and blastoid cytology powerfully risk-stratifies older, frontline MCL patients receiving bendamustine-rituximab, identifying a dismal prognosis subgroup.

A machine learning algorithm accurately classifies MCL versus other B-cell lymphomas using standard peripheral blood flow cytometry data, offering a tool to standardize and accelerate initial diagnosis.